Bristol-Myers deepens CMO deal with Samsung

Piggybacking off an earlier deal, Bristol-Myers Squibb ($BMY) has signed another manufacturing agreement with South Korean giant Samsung. The new project tasks Samsung with making "commercial drug substances and drug product" for a slew of Bristol's biologics, part of the drugmaker's global expansion efforts. News

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

The CRO will transfer most of its Pennsylvania-based biologics laboratory functions to a new, 73,000-square-foot site on Devon Park in Wayne.

Monoclonal antibodies developer Xencor extended a strategic alliance formed in 2016 with Selexis with four commercial license agreements.